INDV FY 2023 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.1B+21.3% YoY

Gross Profit

$919M84.1% margin

Operating Income

-$156M-14.3% margin

Net Income

-$129M-11.8% margin

EPS (Diluted)

$0.01

Cash Flow

Operating Cash Flow

-$300M

Free Cash Flow

-$353M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.0B

Stockholders' Equity

-$191M

Cash & Equivalents

$316M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$901M	+21.3%
Gross Profit	$919M	$750M	+22.5%
Operating Income	-$156M	-$81M	-92.6%
Net Income	-$129M	-$44M	-193.2%